伴EGFR与H3K27M改变的双侧丘脑胶质瘤:整合临床病理特征病例系列
本文报告5例同时携带EGFR与H3K27M改变的双侧丘脑胶质瘤,回顾性分析其临床病理特征与预后,并进行PubMed系统文献复习。患者中位年龄6岁,男女比3:2,震颤和言语障碍为主要表现;中位总生存8个月后3例死于肿瘤进展。作者认为此类双重改变可能代表弥漫性中线胶质瘤H3K27M改变型的新亚型。
要点
- 5例双侧丘脑胶质瘤同时携带EGFR与H3K27M改变,中位年龄6岁(范围3-9岁),男女比3:2。
- 中位总生存8个月,5例中3例死于肿瘤进展。
- 作者认为EGFR改变可能提供潜在分子治疗策略以改善不良预后。
核心结论
- 同时携带EGFR与H3K27M改变可能提示弥漫性中线胶质瘤H3K27M改变型的一个新亚型。
- EGFR改变可能提供潜在分子治疗策略以改善双侧丘脑胶质瘤的不良预后。
- 由于此类肿瘤罕见,需收集更多病例以研究双重改变表型双侧丘脑胶质瘤的发病机制、治疗和临床结局。
研究设计与样本
- 回顾性分析5例同时携带EGFR与H3K27M改变的双侧丘脑胶质瘤患者的临床资料,并进行免疫组化和分子分析。
- 同时使用PubMed进行系统文献复习。
主要发现
- 患者中位年龄6岁(范围3-9岁),男女比为3:2。
- 震颤和言语障碍为主要临床表现。
- 所有病变均位于双侧丘脑,4例中有3例左侧丘脑病变更显著。
- 2例携带EGFR外显子20插入突变,1例携带EGFR外显子7错义突变,2例为EGFR扩增。
- 中位总生存8个月后,3例患者死于肿瘤进展。
局限性
- 由于这些肿瘤罕见,必须收集更多病例来研究具有双重改变表型的双侧丘脑胶质瘤的发病机制、治疗和临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bilateral thalamic gliomas (BTGs) are rare central nervous system tumors, and the outcome is usually dismal. BTG often harbors an EGFR mutation; however, a mutation in H3K27M is rare. We described 5 cases of BTGs harboring concomitant alterations of EGFR and H3K27M and retrospectively analyzed the clinicopathological features and prognosis of this rare entity. METHODS: Clinical data of patients were retrieved, and immunohistochemistry and molecular analyses were performed. In addition, a systematic review of literature was conducted using PubMed. RESULTS: Median patient age was 6 years (range, 3-9 years). The male-to-female ratio was 3:2. Tremors and disturbed speech were the main clinical manifestations. All lesions were located at bilateral thalami, and in 3 of 4 patients, the more significant thalamic lesion was on the left. Two patients harbored insertion mutations in exon 20 of EGFR, 1 missense mutation in exon 7 of EGFR, and 2 EGFR amplifications. After a median overall survival of 8 months, 3 patients died as a result of tumor progression. CONCLUSIONS: Concomitant alterations of EGFR and H3K27M might indicate a new subtype of diffuse midline glioma, H3K27M-altered. In addition, EGFR alterations could provide potential molecular therapeutic strategies to improve the dismal prognosis of BTGs. Due to the rarity of these tumors, more cases must be collected to study the pathogenesis, treatment, and clinical outcomes of BTGs with double alteration phenotypes.
引用
- Xu K, Sun Z, Wang L, et al. Bilateral Thalamic Gliomas Harboring Alterations of EGFR and H3K27M: An Integrated Clinicopathological Characteristics Case Series. World Neurosurg. 2022. PMID: 36195182. doi:10.1016/j.wneu.2022.09.118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。